Europe’s biggest firm, whose sales of Wegovy almost doubled, feels it can ‘meet demands’ of US administration
Europe’s biggest company, Novo Nordisk, has rebuffed fears of a hit to its business from Donald Trump’s threatened tariffs, as it reported better-than-expected revenues after sales of its weight-loss drug Wegovy almost doubled.
Since taking office, the US president has imposed tariffs on Mexico and Canada – since paused for a month – and China, and has said levies of imports from the EU will “definitely happen”.
About Author
More Stories
Australian scientists produce kangaroo embryos using IVF for first time
Doctor faces inquiry after giving his cat a Cat scan at Italian hospital
Rahim Al-Hussaini named as 50th Aga Khan after death of father